$NNNN

Anbio Biotechnology

CIK:0001982708|SEC Filings

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Income Statement [Abstract]
Revenues	$ 8,646,844	$ 8,185,146	$ 6,711,990
Total Revenues	8,646,844	8,185,146	6,711,990
Cost of Revenues	1,103,682	2,299,762	3,351,121
Gross Profit	7,543,162	5,885,384	3,360,869
Operating Expenses
Selling, general and administrative	1,574,117	3,435,790	1,265,240
Research and development	201,305	454,227	134,700
Total operating expenses	1,775,422	3,890,017	1,399,940
Income from operations	5,767,740	1,995,367	1,960,929
Other Income
Interest and investment income	142,023	337,511	165,336
Foreign exchange gain	493,562	20,469	119,419
Others, net	138	19,495	8,025
Total other income	635,723	377,475	292,780
Income before provision for income taxes	6,403,463	2,372,842	2,253,709
Provision for income taxes	0	0	0
Net income	$ 6,403,463	$ 2,372,842	$ 2,253,709
Basic earnings per Class A share (in Dollars per share)	$ 0.147	$ 0.056	$ 0.105
Diluted earnings per Class A share (in Dollars per share)	$ 0.147	$ 0.056	$ 0.105
Weighted average shares outstanding-Class A (in Shares)	43,672,022	42,291,200	21,435,315

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Cash flows from operating activities:
Net income	$ 6,403,463	$ 2,372,842	$ 2,253,709
Adjustments to reconcile net income to net cash (used in) provided by operating activities:
Amortization of right-of-use asset			12,059
Realized loss (gain) from short-term investment	68,003	(337,101)	(163,388)
Net changes in operating assets and liabilities:
Accounts receivable	(2,591,170)	820,166	(1,884,960)
Inventory			353,872
Prepayment	(8,395,507)	(1,910,258)	1,049,599
Prepaid and other current assets	(581,466)	396,271	(305,995)
Rent deposit	0	1,293	1,696
Accounts payable	(1,625,255)	798,104	(580,891)
Other current liabilities	(17,143)	(60,930)	162,666
Net cash (used in) provided by operating activities	(6,739,075)	2,080,387	898,367
Cash flows from investing activities:
Purchase of short-term investment	(19,420,000)	(35,466,235)	(18,544,250)
Sale of short-term investment	15,217,504	35,803,336	20,274,423
Net cash (used in) provided by investing activities	(4,202,496)	337,101	1,730,173
Cash flows from financing activities:
Cash received from the issuance of ordinary shares	7,230,000	0	0
Payment of transaction cost for issuing new shares	(282,550)	(344,605)	(42,835)
Net cash provided by (used in) financing activities	6,947,450	(344,605)	(42,835)
Net change in cash and cash equivalents	(3,994,121)	2,072,883	2,585,705
Cash and cash equivalents at beginning of year	11,760,859	9,687,976	7,102,271
Cash and cash equivalents at end of year	7,766,738	11,760,859	9,687,976
Supplemental disclosure of non-cash financing Activities:
Non-cash deferred offering costs	770,000	0	0
Class A Ordinary Shares
Supplemental disclosure of non-cash financing Activities:
Receivable from issuance	0	0	8,009
Class B Ordinary Shares
Supplemental disclosure of non-cash financing Activities:
Receivable from issuance	$ 0	$ 0	$ 10,000

Consolidated Balance Sheets - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 7,766,738	$ 11,760,859
Accounts receivable, net	3,655,964	1,064,794
Short-term investment	4,134,493	0
Prepayment	14,078,592	5,683,085
Prepaid and other current assets	607,072	25,606
Total Current Assets	30,242,859	18,534,344
Deferred offering cost	0	387,440
TOTAL ASSETS	30,242,859	18,921,784
Current liabilities:
Accounts payable	0	1,625,255
Other current liabilities	87,836	104,979
Total Current Liabilities	87,836	1,730,234
TOTAL LIABILITIES	87,836	1,730,234
Shareholders’ Equity:
Additional paid-in capital	6,563,630	3,780
Retained earnings	23,577,004	17,173,541
TOTAL SHAREHOLDERS’ EQUITY	30,155,023	17,191,550
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	30,242,859	18,921,784
Class A Ordinary Shares
Shareholders’ Equity:
Common stock value	4,389	4,229
Class B Ordinary Shares
Shareholders’ Equity:
Common stock value	$ 10,000	$ 10,000